Skip to main content
Erschienen in: Advances in Therapy 8/2021

09.07.2021 | Original Research

Anterior Segment Optical Coherence Tomography Angiography Assessment of Corneal Vascularisation After Combined Fine-Needle Diathermy with Subconjunctival Ranibizumab: A Pilot Study

verfasst von: Valencia Hui Xian Foo, Mengyuan Ke, Chelsea Qiu Lin Tan, Leopold Schmetterer, Jodhbir S. Mehta, Marcus Ang

Erschienen in: Advances in Therapy | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To describe anterior segment optical coherence tomography angiography (AS-OCTA) imaging to monitor corneal vascularisation (CoNV) and scar reduction after combined fine-needle diathermy (FND) with subconjunctival ranibizumab.

Methods

Prospective clinical study of six eyes from six subjects with corneal scar and CoNV which underwent combined FND with subconjunctival ranibizumab. All eyes were imaged using slit-lamp photography (SLP) and AS-OCTA (Optovue, Inc., Fremont, CA, wavelength: 840 nm) before and after the operation, with two independent masked assessors analysing all images. Main outcome measures were changes in median corneal scar area and vessel density (AS-OCTA) comparing pre- and postoperative imaging up to month 3 and 6.

Results

The mean age of the subjects was 60 ± 23 years, with three males and three females. CoNV and corneal scarring involving the visual axis were present in all eyes, secondary to previous infective keratitis (n = 3), severe blepharokeratoconjunctivitis (n = 2), or chemical injury (n = 1). Follow-up time frame ranged from 2 to 6 months postoperation. There was a reduction in median corneal scar area from 30.2 mm2 (IQR 18.7–38.5) before surgery to 14.8 mm2 (IQR 7.1–19.6) after surgery, with a median reduction of 37.1% (IQR = − 3.1–86.9, p = 0.046). There was also a reduction in median cornea vessel density (AS-OCTA) from 20.8% (IQR 16.1–20.8) before surgery to 17.6% (IQR 14.0–17.6) after surgery, with a median reduction of 15.1% (IQR 13.2–15.1, p < 0.001).

Conclusions

Combined imaging of SLP and AS-OCTA is useful for monitoring treatment response of corneal scarring and CoNV after combined FND with subconjunctival Ranibizumab.
Literatur
1.
Zurück zum Zitat Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264–330.PubMedPubMedCentral Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264–330.PubMedPubMedCentral
2.
Zurück zum Zitat Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12(4):242–9.CrossRef Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12(4):242–9.CrossRef
3.
Zurück zum Zitat Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vis (Lond). 2017;4:28.CrossRef Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vis (Lond). 2017;4:28.CrossRef
4.
Zurück zum Zitat Sharif Z, Sharif W. Corneal neovascularization: updates on pathophysiology, investigations & management. Rom J Ophthalmol. 2019;63(1):15–22.CrossRef Sharif Z, Sharif W. Corneal neovascularization: updates on pathophysiology, investigations & management. Rom J Ophthalmol. 2019;63(1):15–22.CrossRef
5.
Zurück zum Zitat Armitage WJ, Goodchild C, Griffin MD, Gunn DJ, Hjortdal J, Lohan P, Murphy CC, Pleyer U, Ritter T, Tole DM, Vabres B. High-risk corneal transplantation: Recent developments and future possibilities. Transplantation. 2019;103(12):2468.CrossRef Armitage WJ, Goodchild C, Griffin MD, Gunn DJ, Hjortdal J, Lohan P, Murphy CC, Pleyer U, Ritter T, Tole DM, Vabres B. High-risk corneal transplantation: Recent developments and future possibilities. Transplantation. 2019;103(12):2468.CrossRef
6.
Zurück zum Zitat Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf. 2012;10(2):67–83.CrossRef Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf. 2012;10(2):67–83.CrossRef
7.
Zurück zum Zitat Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41(8):2148–53.PubMed Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41(8):2148–53.PubMed
8.
Zurück zum Zitat Le VN, Hou Y, Bock F, Cursiefen C. Supplemental anti Vegf A-therapy prevents rebound neovascularisation after fine needle diathermy treatment to regress pathological corneal (LYMPH) angiogenesis. Sci Rep. 2020;10(1):1–8.CrossRef Le VN, Hou Y, Bock F, Cursiefen C. Supplemental anti Vegf A-therapy prevents rebound neovascularisation after fine needle diathermy treatment to regress pathological corneal (LYMPH) angiogenesis. Sci Rep. 2020;10(1):1–8.CrossRef
9.
Zurück zum Zitat Koenig Y, Bock F, Kruse FE, Stock K, Cursiefen C. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea. 2012;31:887–92.CrossRef Koenig Y, Bock F, Kruse FE, Stock K, Cursiefen C. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea. 2012;31:887–92.CrossRef
10.
Zurück zum Zitat Elbaz U, Mireskandari K, Shen C, Ali A. Corneal fine needle diathermy with adjuvant bevacizumab to treat corneal neovascularization in children. Cornea. 2015;34(7):773–7.CrossRef Elbaz U, Mireskandari K, Shen C, Ali A. Corneal fine needle diathermy with adjuvant bevacizumab to treat corneal neovascularization in children. Cornea. 2015;34(7):773–7.CrossRef
11.
Zurück zum Zitat Hussain R, Savant V. Fine-needle diathermy with simultaneous subconjunctival bevacizumab. Semin Ophthalmol. 2017;32(5):550–2.CrossRef Hussain R, Savant V. Fine-needle diathermy with simultaneous subconjunctival bevacizumab. Semin Ophthalmol. 2017;32(5):550–2.CrossRef
12.
Zurück zum Zitat Zou L, Lai H, Zhou Q, Xiao F. Lasting controversy on ranibizumab and bevacizumab. Theranostics. 2011;1:395.CrossRef Zou L, Lai H, Zhou Q, Xiao F. Lasting controversy on ranibizumab and bevacizumab. Theranostics. 2011;1:395.CrossRef
13.
Zurück zum Zitat Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short-and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1375–82.CrossRef Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Short-and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1375–82.CrossRef
14.
Zurück zum Zitat Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726–33.CrossRef Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726–33.CrossRef
15.
Zurück zum Zitat Ferrari G, Dastjerdi MH, Okanobo A, Cheng SF, Amparo F, Nallasamy N, Dana R. Topical ranibizumab as a treatment of corneal neovascularization. Cornea. 2013;32(7):992.CrossRef Ferrari G, Dastjerdi MH, Okanobo A, Cheng SF, Amparo F, Nallasamy N, Dana R. Topical ranibizumab as a treatment of corneal neovascularization. Cornea. 2013;32(7):992.CrossRef
16.
Zurück zum Zitat Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865–81.CrossRef Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, Vos AM, Lowman HB. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865–81.CrossRef
17.
Zurück zum Zitat Kim JH, Seo HW, Han HC, Lee JH, Choi SK, Lee D. The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study. Korean J Ophthalmol. 2013;27(4):235–42.CrossRef Kim JH, Seo HW, Han HC, Lee JH, Choi SK, Lee D. The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study. Korean J Ophthalmol. 2013;27(4):235–42.CrossRef
18.
Zurück zum Zitat Cheng SF, Ferrari G, Okanobo A, et al. Sustained efficacy of topical bevacizumab in the treatment of corneal neovascularization (NV). Invest Ophthalmol Vis Sci. 2011;154(6):940–48.e1. Cheng SF, Ferrari G, Okanobo A, et al. Sustained efficacy of topical bevacizumab in the treatment of corneal neovascularization (NV). Invest Ophthalmol Vis Sci. 2011;154(6):940–48.e1.
19.
Zurück zum Zitat Anijeet DR, Zheng Y, Tey A, Hodson M, Sueke H, Kaye SB. Imaging and evaluation of corneal vascularization using fluorescein and indocyanine green angiography. Invest Ophthalmol Vis Sci. 2012;53:650–8.CrossRef Anijeet DR, Zheng Y, Tey A, Hodson M, Sueke H, Kaye SB. Imaging and evaluation of corneal vascularization using fluorescein and indocyanine green angiography. Invest Ophthalmol Vis Sci. 2012;53:650–8.CrossRef
20.
Zurück zum Zitat Kirwan RP, Zheng Y, Tey A, Anijeet D, Sueke H, Kaye SB. Quantifying changes in corneal neovascularization using fluorescein and indocyanine green angiography. Am J Ophthalmol. 2012;154:850–8.CrossRef Kirwan RP, Zheng Y, Tey A, Anijeet D, Sueke H, Kaye SB. Quantifying changes in corneal neovascularization using fluorescein and indocyanine green angiography. Am J Ophthalmol. 2012;154:850–8.CrossRef
21.
Zurück zum Zitat Di Lee W, Devarajan K, Chua J, Schmetterer L, Mehta JS, Ang M. Optical coherence tomography angiography for the anterior segment. Eye Vision. 2019;6(1):4.CrossRef Di Lee W, Devarajan K, Chua J, Schmetterer L, Mehta JS, Ang M. Optical coherence tomography angiography for the anterior segment. Eye Vision. 2019;6(1):4.CrossRef
22.
Zurück zum Zitat Ong HS, Tey KY, Ke M, et al. A pilot study investigating anterior segment optical coherence tomography angiography as a non-invasive tool in evaluating corneal vascularisation. Sci Rep. 2021;11:1212.CrossRef Ong HS, Tey KY, Ke M, et al. A pilot study investigating anterior segment optical coherence tomography angiography as a non-invasive tool in evaluating corneal vascularisation. Sci Rep. 2021;11:1212.CrossRef
23.
Zurück zum Zitat Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vision. 2017;4(1):28.CrossRef Feizi S, Azari AA, Safapour S. Therapeutic approaches for corneal neovascularization. Eye Vision. 2017;4(1):28.CrossRef
24.
Zurück zum Zitat Ahn YJ, Hwang HB, Chung SK. Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment. Korean J Ophthalmol. 2014;28(2):177–80.CrossRef Ahn YJ, Hwang HB, Chung SK. Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment. Korean J Ophthalmol. 2014;28(2):177–80.CrossRef
25.
Zurück zum Zitat Sener E, Yuksel N, Yildiz DK, Yilmaz B, Ozdemir O, Caglar Y, Degirmenci E. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res. 2011;36(11):1005–13.CrossRef Sener E, Yuksel N, Yildiz DK, Yilmaz B, Ozdemir O, Caglar Y, Degirmenci E. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res. 2011;36(11):1005–13.CrossRef
26.
Zurück zum Zitat Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981;99:599–604.CrossRef Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981;99:599–604.CrossRef
27.
Zurück zum Zitat Hos D, Le VN, Hellmich M, Siebelmann S, Roters S, Bachmann BO, Cursiefen C. Risk of corneal graft rejection after high-risk keratoplasty following fine-needle vessel coagulation of corneal neovascularization combined with bevacizumab: a pilot study. Transplant Direct. 2019;5(5):e452.CrossRef Hos D, Le VN, Hellmich M, Siebelmann S, Roters S, Bachmann BO, Cursiefen C. Risk of corneal graft rejection after high-risk keratoplasty following fine-needle vessel coagulation of corneal neovascularization combined with bevacizumab: a pilot study. Transplant Direct. 2019;5(5):e452.CrossRef
28.
Zurück zum Zitat Le VN, Schneider AC, Scholz R, Bock F, Cursiefen C. Fine needle-diathermy regresses pathological corneal (lymph) angiogenesis and promotes high-risk corneal transplant survival. Sci Rep. 2018;8(1):1–8. Le VN, Schneider AC, Scholz R, Bock F, Cursiefen C. Fine needle-diathermy regresses pathological corneal (lymph) angiogenesis and promotes high-risk corneal transplant survival. Sci Rep. 2018;8(1):1–8.
29.
Zurück zum Zitat Oie Y, Nishida K. Evaluation of corneal neovascularization using optical coherence tomography angiography in patients with limbal stem cell deficiency. Cornea. 2017;36(Suppl 1):S72–5.CrossRef Oie Y, Nishida K. Evaluation of corneal neovascularization using optical coherence tomography angiography in patients with limbal stem cell deficiency. Cornea. 2017;36(Suppl 1):S72–5.CrossRef
30.
Zurück zum Zitat Cai Y, Del Barrio JL, Wilkins MR, Ang M. Serial optical coherence tomography angiography for corneal vascularization. Graefes Arch Clin Exp Ophthalmol. 2017;255(1):135–9.CrossRef Cai Y, Del Barrio JL, Wilkins MR, Ang M. Serial optical coherence tomography angiography for corneal vascularization. Graefes Arch Clin Exp Ophthalmol. 2017;255(1):135–9.CrossRef
32.
Zurück zum Zitat Fung SS, Stewart RM, Dhallu SK, Sim DA, Keane PA, Wilkins MR, Tuft SJ. Anterior segment optical coherence tomographic angiography assessment of acute chemical injury. Am J Ophthalmol. 2019;1(205):165–74.CrossRef Fung SS, Stewart RM, Dhallu SK, Sim DA, Keane PA, Wilkins MR, Tuft SJ. Anterior segment optical coherence tomographic angiography assessment of acute chemical injury. Am J Ophthalmol. 2019;1(205):165–74.CrossRef
34.
Zurück zum Zitat Ang M, Cai Y, MacPhee B, Sim DA, Keane PA, Sng CC, Egan CA, Tufail A, Larkin DF, Wilkins MR. Optical coherence tomography angiography and indocyanine green angiography for corneal vascularisation. Br J Ophthalmol. 2016;100(11):1557–63.CrossRef Ang M, Cai Y, MacPhee B, Sim DA, Keane PA, Sng CC, Egan CA, Tufail A, Larkin DF, Wilkins MR. Optical coherence tomography angiography and indocyanine green angiography for corneal vascularisation. Br J Ophthalmol. 2016;100(11):1557–63.CrossRef
35.
Zurück zum Zitat Ang M, Cai Y, Shahipasand S, Sim DA, Keane PA, Sng CC, Egan CA, Tufail A, Wilkins MR. En face optical coherence tomography angiography for corneal neovascularisation. Br J Ophthalmol. 2016;100(5):616–21.CrossRef Ang M, Cai Y, Shahipasand S, Sim DA, Keane PA, Sng CC, Egan CA, Tufail A, Wilkins MR. En face optical coherence tomography angiography for corneal neovascularisation. Br J Ophthalmol. 2016;100(5):616–21.CrossRef
36.
Zurück zum Zitat Faraj LA, Elalfy MS, Said DG, Dua HS. Fine needle diathermy occlusion of corneal vessels. Br J Ophthalmol. 2014;98(9):1287–90.CrossRef Faraj LA, Elalfy MS, Said DG, Dua HS. Fine needle diathermy occlusion of corneal vessels. Br J Ophthalmol. 2014;98(9):1287–90.CrossRef
Metadaten
Titel
Anterior Segment Optical Coherence Tomography Angiography Assessment of Corneal Vascularisation After Combined Fine-Needle Diathermy with Subconjunctival Ranibizumab: A Pilot Study
verfasst von
Valencia Hui Xian Foo
Mengyuan Ke
Chelsea Qiu Lin Tan
Leopold Schmetterer
Jodhbir S. Mehta
Marcus Ang
Publikationsdatum
09.07.2021
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 8/2021
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-021-01849-w

Weitere Artikel der Ausgabe 8/2021

Advances in Therapy 8/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.